SCHEMBL685723

SCHEMBL685723

C=CC(=O)OC1C(=O)OCC1(C)C

nearest known ligand 0.66

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CTSV O60911 1/20 0.36
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
AR P10275 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9957780 1.00 CTSV (0.36) CTSVCTSLCTSSCTSKAR
SCHEMBL1351991 1.00 CTSV (0.36) CTSVCTSLCTSSCTSKAR
SCHEMBL12847902 0.85 CTSV (0.32) CTSVCTSLCTSSCTSK
SCHEMBL685114 0.84 CTSV (0.34) CTSVCTSLCTSSCTSKAR
SCHEMBL28066407 0.84 LMNA (0.31)
SCHEMBL25457735 0.83 CTSV (0.35) CTSVCTSLCTSSCTSKAR
SCHEMBL25457736 0.83 CTSV (0.35) CTSVCTSLCTSSCTSKAR
SCHEMBL25457734 0.83 CTSV (0.35) CTSVCTSLCTSSCTSKAR
SCHEMBL1697108 0.82 CTSV (0.35) CTSVCTSLCTSSCTSK
SCHEMBL12501615 0.81 CTSV (0.33) CTSVCTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3785692-A1 DENTAL COMPOSITION DENTSPLY SIRONA Inc. (US) 2021-03-03 EP claimed
WO-2006052985-A1 LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-05-18 WO claimed
US-20060096158-A1 Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same ROBINSON J M 2006-05-11 US claimed
EP-3253735-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2021-03-31 EP disclosed
US-10780145-B2 In situ forming hydrogel and method using same ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-09-22 US disclosed
EP-3004050-B1 CYANOSTILBENES ROLIC TECH AG (CH) 2020-09-02 EP disclosed
CN-111533668-A Cyanostilbenes 罗利克技术有限公司 2020-08-14 CN disclosed
EP-2709613-B2 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC (US) 2020-08-12 EP disclosed
US-10456414-B2 Methods for treating HCV GILEAD PHARMASSET LLC (US) 2019-10-29 US disclosed
EP-2539316-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2019-10-23 EP disclosed
US-10329486-B2 Cyanostilbenes ROLIC AG (CH) 2019-06-25 US disclosed
US-6406830-B2 BIS(SULFONIUM METHYL)KETONE BISPERFLUOROALKANESULFONATE ACID GENERATOR WITH TRIPHENYLSULFONIUM OR DIPHENYLIODONIUM SALTS, AND A RESIN HAVING A UNIT UNSTABLE TO AN ACID, SUCH AS 2-ALKYL-2-ADAMANTYL (METH)ACRYLATE; RESOLUTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-18 US disclosed
US-6383713-B1 ADAMANTYL ACRYLATE POLYMERS AND ACID GENERATORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-05-07 US disclosed
US-20020048720-A1 Positive photoresist composition FUJIFILM CORPORATION (JP) 2002-04-25 US disclosed
US-20020015913-A1 Chemical amplifying type positive resist composition and sulfonium salt SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-07 US disclosed
US-20020006582-A1 Chemical amplification type positive resist compositions and sulfonium salts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-01-17 US disclosed
EP-1167349-A1 Chemical amplifying type positive resist composition and sulfonium salt SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-01-02 EP disclosed
EP-1154321-A1 Chemical amplification type positive resist compositions and sulfonium salts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-14 EP disclosed
EP-1041442-A1 Chemical amplification type positive resist SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-10-04 EP disclosed
EP-1020767-A1 Chemical amplification type positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10456414-B2 Methods for treating HCV HAVCR2, HCCS, LIPC CTSV 134/4885CTSL 468/4885CTSS 466/4885
US-10780145-B2 In situ forming hydrogel and method using same CRYAA, CD44, HSF1 CTSV 4535/4885CTSL 2997/4885CTSS 3618/4885
US-10329486-B2 Cyanostilbenes LATS1, LATS2, CRY1 CTSV 953/4885CTSL 1875/4885CTSS 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.